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Abstract
Background: Several options are available for the treatment of chronic rhinosinusitis (CRS), but disease control
remains elusive for many patients. Recently, literature has emerged describing anti-IgE monoclonal antibody as a
potential therapy for CRS. However, its effectiveness and safety are not well known. The purpose of this systematic
review was to assess the effectiveness and safety of anti-IgE therapy and to identify evidence gaps that will guide
future research for the management of CRS.
Methods: Methodology was registered with PROSPERO (No. CRD42014007600). A comprehensive search was
performed of standard bibliographic databases, Google Scholar, and clinical trials registries. Only randomized
controlled trials assessing anti-IgE therapy in adult patients for the treatment of CRS were included. Two independent
reviewers extracted data using a pre-defined extraction form and performed quality assessment using the Cochrane
risk of bias tool and the GRADE framework.
Results: Two studies met our inclusion criteria. When comparing anti-IgE therapy to placebo, there was a significant
difference in Lund-McKay score (p = 0.04) while no difference was seen for percent opacification on computed
tomography (CT). At 16 weeks, treatment led to a decrease in clinical polyp score. No significant difference was seen
with regard to quality of life (Total Nasal Symptom Severity (TNSS), p < 0.21; Sinonasal Outcome Test 20 (SNOT-20),
p < 0.60), and no serious complications were reported in either trial. Based on the quality assessment, studies were
deemed to be of moderate risk of bias and a low overall quality of evidence.
Conclusions: There is currently insufficient evidence to determine the effectiveness of anti-IgE monoclonal antibody
therapy for the treatment of CRS.
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Background
Chronic rhinosinusitis (CRS) is a condition characterized
by persistent inflammation of the paranasal sinus mucosa
with concomitant bacterial colonization. It is a disease of
high prevalence, especially in women and older adults [1].
It affects 14.2 % of the adult US population and accounts
for between 18 and 22 million annual office visits [2–4].
In Canada, CRS affects about 5 % of adults and accounts
for close to one million prescriptions annually [1]. The
symptoms of CRS significantly lower the physical and
psychological well-being of patients, which directly leads
to decreased patient quality of life [5–8].
Recent advances in understanding of the pathophysi-
ology of CRS have improved management paradigms,
which have resulted in improved quality of life for CRS
patients [8]. Several medical and surgical alternatives are
available, ranging from corticosteroids and antibiotics to
functional endoscopic sinus surgery. Despite improved
outcomes for CRS patients, these treatment strategies
are limited since they focus on symptom relief and
inflammatory reduction rather than causal abatements.
Consequently, disease control remains elusive for many
patients, particularly for those with nasal polyposis and
comorbid asthma [9]. Current investigations have shifted
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focus to target the genesis of dysregulated mucosal im-
mune and barrier responses and the resultant chronic
sinonasal inflammation states [10, 11]. Based on the pro-
posed role of eosinophils and Th2 cytokines in CRS,
IgE—a key inflammatory mediator—has been implicated
in the pathophysiology of CRS of some patients [12].
Similarly, literature has emerged that describes anti-IgE
monoclonal antibody (omalizumab) as a potential injec-
tion therapy for CRS [13–17].
There are several studies that examine the role of anti-
IgE monoclonal antibody in the management of CRS
[13–15, 18–20], but its effectiveness and safety are not
well known. The purpose of this systematic review was
twofold: (1) to assess the effectiveness and safety of anti-
IgE monoclonal antibody therapy for the treatment of
adult patients with CRS and (2) to identify evidence gaps
that will guide future research on anti-IgE monoclonal
antibody therapy for the management of CRS.
Methods
We undertook a systematic review based on an a
priori protocol that was registered with PROSPERO (No.
CRD42014007600) [21]. This systematic review has been
reported according to the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) state-
ment [22] (Additional file 1).
Search strategy and selection process
A comprehensive search was performed of standard
bibliographic databases (MEDLINE, EMBASE, CINAHL,
Web of Science, and The Cochrane Library). Google
Scholar was searched as a source of gray literature. A
manual search of relevant journals and conference pro-
ceedings was also performed. The reference lists of in-
cluded articles as well as relevant review articles were
screened to identify any relevant studies that were not
previously identified. ClinicalTrials.gov, International Clin-
ical Trials Registry Platform (ICTRP), and EU Clinical
Trials Registry were also searched to identify any on-
going or completed trials. All studies written in English
published between January 1970 and April 2014 were
included. The following key words and Mesh controlled
vocabulary terms were used in varying combinations:
antibodies, monoclonal; antibodies, anti-idiotypic; anti-
bodies, monoclonal, humanized; sinusitis; rhinitis; and
nasal polyps (Appendix 1). The MEDLINE search was
adapted to the other databases.
Titles and abstracts of the retrieved articles were then
screened for their potential relevance by a single re-
viewer (SK). The full-text versions of potentially relevant
articles were obtained and assessed using a pre-defined
eligibility form by the same reviewer. Only randomized
controlled trials (RCTs) assessing anti-IgE monoclonal
antibody therapy in adult (>18) patients for the treat-
ment of CRS were included.
Eligibility criteria
(a)Population: adult patients (>18) with CRS, even if
the condition was poorly defined.
(b)Intervention and comparison: studies comparing
anti-IgE monoclonal antibody therapy with placebo
or another therapy, given for at least 16 weeks;
anti-IgE in combination with other therapies or as
an adjuvant therapy was not assessed here.
(c)Outcomes (not used for selection of studies):
outcomes were collected for any period of follow-up.
(d)Primary outcomes: change in computed tomography
(CT) score, change in clinical polyp score, and
change in quality of life.
(e)Secondary outcomes: change in cellular
inflammation, change in nasal airflow, change in
olfaction, adverse events, change in systemic IgE
levels, and change in spirometric results.
(f ) Study design: RCTs.
(g)Timing: studies published or reported as of 1970
were included (1970 was the earliest available year
on standard bibliographic databases).
(h)Language: studies written in the English language
were included.
Data extraction
Two independent reviewers (JQ and JB) read full-text re-
ports and extracted data using a pre-defined extraction
form. Data were extracted on the following: title, first
author, year of publication, general study and patient
characteristics, study methods, and outcome definitions
and data. Refer to Table 1 for details on data extraction
elements. Discrepancies were settled by consensus and
discussion amongst the reviewers.
Risk of bias assessment
The two reviewers also performed independent risk of
bias assessment of included studies using the Cochrane
risk of bias tool [23]. Discrepancies were resolved by con-
sensus. Random sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding of
outcome assessment, incomplete outcome data, selective
reporting, and other sources of bias are the domains
of the Cochrane tool. Other sources of potential bias
assessed included pharmaceutical company involvement.
Each domain was assessed as at a low, unclear, or high risk
of bias; these assessments are incorporated in the GRADE
judgment of the quality of evidence [24].
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Data analyses
Study characteristics are shown in tables and described
narratively. No meta-analysis was carried out because
the two included studies used different outcome measures.
Where possible, effect estimates for individual studies
were reported with mean differences (MDs) and 95 % con-
fidence intervals (CIs), using Review Manager (version
5.3). Where needed, a correlation coefficient of 0.25 was
used to impute standard deviations for means used in
change from baseline calculations.
Overall quality of evidence
Two independent reviewers (JQ and JB) used the GRADE
framework to judge the overall quality of evidence [25–29].
This assessment involves judgment in the following
domains: risk of bias, publication bias, imprecision, incon-
sistency, and indirectness. GRADE assessments were per-
formed for the body of evidence for each outcome.
Results
A study flow diagram is presented in Fig. 1. Our search
identified 239 records, 14 of which remained after remov-
ing duplicate entries and excluding non-eligible articles
from title and abstract screening. After application of our
inclusion criteria by reviewing these potential articles in
full-text, two RCTs with a placebo comparison were in-
cluded. No studies with another therapy as a comparison
were identified. No additional ongoing or completed trials
were located on ClinicalTrials.gov, ICTRP, and EU Clinical
Trials Registry.
Characteristics of studies
Table 2 represents study characteristics of the two in-
cluded studies. Both studies assessed anti-IgE monoclonal
antibody therapy in adult (>18 years old) CRS patients
with serum IgE between 30 and 700 kU/mL. All patients
in the treatment group had nasal polyposis and comorbid
asthma. The Gevaert et al. [16] study was a multisite RCT
conducted at two university hospitals in Belgium, while
the Pinto et al. [17] study was a single-site RCT conducted
in the USA. Standard drug doses and dosing frequencies
used for the treatment of allergic asthma were applied in
the included studies. Sample sizes for the studies were
small (23 and 14 patients, respectively).
Risk of bias assessment
Table 3 outlines the risk of bias assessments by domain
for included studies. Overall, studies were deemed at a
moderate risk of bias for outcomes.
There was an adequate random sequence generation in
the Gevaert et al. [16] study, but this information was not
available in the Pinto et al. [17] study. It was unclear
whether allocation concealment took place in either study.
We assessed “blinding of participants and personnel”
across all outcomes, and in both studies, it was not pos-
sible to determine whether personnel (i.e., healthcare
providers, outcome assessors) were blinded. In the
Table 1 Data extraction elements







• Polyp staging score used
• Inclusion criteria
• Exclusion criteria
• Subjects (total (n), men (n), women (n))
• Age (mean, median, range)
• Number excluded
• Study duration
Data extraction elements for the treatment (anti-IgE) and placebo arms
• Subjects (total n, subjects with sinusitis and polyps (n), subjects with
sinusitis without polyps (n), men (n), women (n), % subjects with
asthma, % subjects with history of immunotherapy, subjects with
allergy (n, %), number of dropouts/withdrawals from study)
• Age (mean, median, range)




• Dosing regimen, dose amount, duration, frequency
• Pre-CT score ± SD, post-CT score ± SD, length of follow-up, sample
size
• Pre-clinical polyp score ± SD, post-clinical polyp score ± SD, length
of follow-up, sample size
• Pre-quality of life instrument (SF-36, AQLQ, RSOM-31, TNSS, SNOT-20)
± SD, post-quality of life instrument (SF-36, AQLQ, RSOM-31, TNSS,
SNOT-20) ± SD, length of follow-up, sample size
• Pre-cellular inflammation (eosinophil count) ± SD, post-cellular
inflammation (eosinophil count) ± SD, length of follow-up, sample
size
• Pre-nasal airflow (PNIF) ± SD, post-nasal airflow (PNIF) ± SD, length
of follow-up, sample size
• Pre-olfaction (UPSIT) ± SD, post-olfaction (UPSIT) ± SD, length of
follow-up, sample size
• Pre-systemic IgE levels ± SD, post-systemic IgE levels ± SD, length of
follow-up, sample size
• Pre-spirometric result ± SD, post-spirometric result ± SD, length of
follow-up, sample size
• List of adverse events
PNIF peak nasal inspiratory flow, SF-36 36-Item Short Form Health Survey,
AQLQ Asthma Quality of Life Questionnaire, RSOM-31 Rhinosinusitis Outcome
Measure 31, TNSS Total Nasal Symptom Severity, SNOT-20 Sinonasal Outcome
Test 20, UPSIT University of Pennsylvania Smell Identification Test
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Gevaert et al. [16] study, participants were not aware of
the group (treatment vs. placebo) they had been allocated
to. This information was unclear in the Pinto et al. [17]
study. Loss-to-follow-up and handling of missing data are
important aspects of attrition bias, and both studies were
either at low or unclear risk of bias for all outcomes,
respectively. In the Gevaert et al. [16] study, one patient
was withdrawn and four control patients were excluded;
this may have resulted in an overestimate of the treatment
effects. There were no dropouts in the Pinto et al. [17]
study, and all recruited patients completed the study mea-
sures and were analyzed. Studies were also at unclear and
low risk for selective reporting bias. Study sponsorship
bias (other bias) was not an issue in these studies.
Effects of intervention
When comparing anti-IgE monoclonal antibody therapy
to placebo (Table 4), there was a significant difference in
Lund-McKay score [30] in one study. Based on median
data, groups did not appear to be different for percent
opacification on CT.
In the study by Gevaert et al. [16], there was a de-
crease in clinical polyp score in the treatment group
compared to the placebo group at 16 weeks (Table 4). In
the study by Pinto et al. [17], a MD could not be calcu-
lated because of the ambiguity in data handling.
Several quality of life measures were reported (Table 4).
It was unclear whether groups were statistically different
for Asthma Quality of Life Questionnaire (AQLQ) be-
cause of the poor reporting of the p value and absence of
data to calculate a CI. Total Nasal Symptom Severity
(TNSS) and Sinonasal Outcome Test 20 (SNOT-20) were
not statistically significant. Authors did not compare
groups for the 36-Item Short Form Health Survey (SF-36)
or Rhinosinusitis Outcome Measure-31 (RSOM-31).
A few secondary outcomes were measured. Groups
were not different for eosinophil count, peak nasal in-
spiratory flow (PNIF), and olfactory change, measured
with the University of Pennsylvania Smell Identification
Test (UPSIT) (Table 4). Neither study reported on mea-
sures addressing changes in systemic IgE levels or spiro-
metric results.
No serious adverse events were reported with anti-IgE
monoclonal antibody therapy in either trial. The com-
mon cold was the only adverse event that occurred
more frequently (p = 0.02) in patients receiving anti-IgE
Fig. 1 PRISMA 2009 flow diagram. From: Moher D, Liberate A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for
Systematic Reviews and Meta-Analysis: The PRISMA Statement. Plos Med 6(6): e100097. doi:10.1371/journal.pmed100097
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monoclonal antibody therapy in comparison to placebo
(Table 4). With only 37 included patients in this review,
however, the sample is inadequate to make global state-
ments of the safety of this therapy in this population. At
this time, safety data from the use of anti-IgE mono-
clonal antibody therapy in allergic asthma alone should
be observed.
Discussion
To date, very few studies have assessed the effectiveness
and safety of anti-IgE monoclonal antibody therapy for
the management of CRS. As demonstrated in our re-
view, there were only two RCTs comparing anti-IgE
monoclonal antibody therapy against placebo and we did
not locate any studies evaluating this treatment against
other therapies. In this study, GRADE assessments re-
vealed that there is currently a low overall quality of
evidence for recommendations regarding anti-IgE mono-
clonal antibody therapy for the treatment of CRS (see
Table 5). Most commonly, each outcome measure was
reported by only one study and most outcomes were not
statistically significant. Furthermore, the included studies
had several important methodological limitations, lead-
ing to limited overall quality of evidence. Due to the few
included studies with small sample sizes and marked
heterogeneity, results were also imprecise and could not
be assessed for consistency.
The use of daily saline irrigation, intranasal topical
corticosteroids, and/or antibiotics comprise the most
commonly utilized agents as part of the CRS treatment
protocol. These strategies address the core symptoms by
reducing the overall mucosal inflammatory and bacterial
burden of the paranasal sinus mucosa. In clinical cases
that are poorly responsive to medical therapy, surgical
evaluation is often considered. Endoscopic sinus surgery
provides an effective means of improving symptom con-
trol, and it has been shown to directly improve the health
utility values of patients with CRS [8]. However, despite
advances in modern treatment strategies, managing pa-
tient symptoms of CRS continues to pose challenges for
Table 2 Study characteristics of the two included studies
Study characteristics
Omalizumab is effective in allergic and nonallergic patients
with nasal polyps and asthma
A randomized, double-blind, placebo-controlled trial of anti-IgE
for chronic rhinosinusitis
First author Gevaert Pinto
Publication year 2013 2010
Country Belgium USA
Funding source Ghent University, Flemish Scientific Research Board, Belgian
Research Fund, Interuniversity Attraction Poles Program,
Global Allergy and Asthma European Network, Novartis
Genentech and McHugh Research Fund, Dennis W. Jahnigen
Career Development Award (American Geriatrics Society)
Study design RCT RCT
Inclusion criteria Age ≥18 with CRSwNP, comorbid asthma for >2 years,
serum IgE between 30 and 700 kU/mL
Age 18–75, >12 weeks of symptoms with confirmation on CT
and nasal endoscopy, serum IgE between 30 and 700 kU/mL













Total (n) = 23 Total (n) = 14
Men (n) = N/A Men (n) = 10
Women (n) = N/A Women (n) = 4
Age Mean = N/A Mean = 45.85
Median = N/A Median = N/A
Range = 42–56 Range = N/A
Drug dose Max dose of 375 mg 0.016 mg/kg per IU total serum IgE/mL
Dosing frequency Every 2 weeks (eight injections in total); every month
(four injections in total)
At enrollment and every 4 weeks for the 6 months duration
Study duration 20 weeks (16 weeks follow-up) 6 months
RCT randomized controlled trial, CRS chronic rhinosinusitis, N/A not available
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healthcare providers with many patients not responding
or only temporarily responding to these therapeutic inter-
ventions [31].
In recent years, anti-IgE monoclonal antibody was pro-
posed as a sole or adjuvant therapy to improve outcomes
in CRS management paradigms [13–17]. Like asthma,
CRS for some patients has been found to be associated
with local infiltration of polyclonal IgE—a key mediator in
the tissue inflammatory process [10, 32]. Staphylococcus
aureus enterotoxins are believed to act as superantigens
and induce local IgE formation combined with eosino-
philic tissue inflammation [32]. Similarly, other causes of
local IgE production such as fungal antigen may increase
the inflammatory load in CRS [33].
Theoretically, use of anti-IgE monoclonal antibody ther-
apy in CRS makes biologic sense, but there is insufficient
research evidence to determine whether it is clinically
effective overall or for any subset of disease. If so, it may
have important implications for the management para-
digm for CRS since local infiltration of IgE and concurrent
eosinophilic tissue inflammation are present in up to 80 %
of Caucasian patients with CRS [34].
To our knowledge, this systematic review is the first of
its kind, setting out to provide a synthesis of the avail-
able evidence concerning the use of anti-IgE monoclonal
antibody in patients with CRS. Overall, there was little
evidence to draw definitive conclusions regarding the
effectiveness of anti-IgE monoclonal antibody for the
management of CRS. Well-designed RCTs with adequate
power are needed to further assess the effectiveness of
this treatment in the CRS with nasal polyps and asthma
population in the future. In addition, despite several pub-
lished studies demonstrating safety of anti-IgE monoclonal
antibody therapy when used to treat diseases such as aller-
gic asthma and allergic rhinitis [35–37], more research is
needed to further characterize its safety profile. Nonethe-
less, based on current evidence, a trial of anti-IgE mono-
clonal antibody therapy seems to be a biologically valid
option for some patients with CRS who do not respond to
conventional treatment regimens.
The greatest limitation of the included studies is the
poor reporting of outcome measures, which made it diffi-
cult to assess and interpret the reported data. Other items
such as standard deviations for means were not reported;
authors should adhere to the Consolidated Standards of
Reporting Trials (CONSORT) guideline when reporting
future trials [38]. In addition, while the Pinto et al. [17]
trial included patients who were already refractory to mul-
tiple treatments (i.e., population applicability), the Gevaert
et al. [16] trial had one patient who withdrew and four
placebo patients who were excluded from the study. This
affects the assessment of clinical heterogeneity for future
meta-analyses, should more studies become available. The
variable qualities, definitions, and follow-ups were also
Table 3 Risk of bias assessments by domain for included studies
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Table 4 Evidence summary table






Change in CT score
Lund-McKay Score (change in score
from baseline)
Gevaert Mean (no CI), 4.0 vs. −0.5 (improvement
at 16 weeks); p = 0.04
See comment 1 (23) Low Authors state that scores improved with treatment
over control at 16 weeks.
Percent opacification on CT (median
change in % inflammation from
baseline)
Pinto Median (IQR), 13.1 % (4.7 to 29.9) vs.
5.9 % (−11.6 to 23.0)
Not estimable 1 (14) Low (−) median value means reduced inflammation at
6 months.
Change in clinical polyp score
Total nasal endoscopic polyp score
(change in score from baseline;
score 0 to 4, 4 = largest)
Gevaert;
Pinto
Mean (SDa), −2.67 (2.09) vs. −0.12 (0.99)
(smaller polyp size at 16 weeks); see
comment
MD −2.55 (−3.81 to −1.29);
MD could not be calculated
in Pinto et al. trial due to
ambiguity in data handling
1 (23);
1 (14)
Low Pinto et al. trial provided mean data despite
nonparametric statistical test. (−) value for MD
means greater decrease in polyp size from baseline
with anti-IgE monoclonal antibody therapy.
Change in quality of life
SF-36 (change in score from baseline;
physical health, mental health)
Gevaert Not provided Not estimable 1 (23) Low Authors did not compare change from baseline
between groups.
AQLQ (change in score from
baseline)
Gevaert Mean (no CI), 0.81 vs. 0.27 (improvement
at 16 weeks)
See comment 1 (23) Low Data poorly reported; unclear whether p = 0.003
refers to difference in treatment arm from baseline
or a comparison from baseline between groups.
RSOM-31 (change in score from
baseline)
Gevaert Not provided Not estimable 1 (23) Low Authors did not compare change from baseline
between groups.
TNSS Pinto Median, −1 vs. 0; p < 0.21 Not estimable 1 (14) Low (−) median value means reduced nasal symptoms
at 6 months.
SNOT-20 (change in mean from
baseline)
Pinto Mean (SDa), 0.98 (1.15) vs. 0.75 (1.76)
(improvement at 16 weeks); p < 0.60
MD 0.23 (−1.33 to 1.79) 1 (14) Low (+) value for MD means greater control of nasal
symptoms from baseline with anti-IgE monoclonal
antibody therapy.
Secondary outcomes
Change in cellular inflammation
Eosinophil count (nasal lavage;
median change from baseline)
Pinto Median (IQR), 2 (−11.75 to 9.25) vs.
9 (−2.75 to 26.5); p < 0.47
Not estimable 1 (8) Low (+) median value means increased eosinophil
count at 6 months.
Change in nasal airflow
PNIF (median change from baseline) Pinto Median (IQR), −0.9 (−20.0 to 40.0) vs.
−7.5 (−30.0 to 13.3); p < 0.31
Not estimable 1 (12) Low (−) median value means reduced nasal airflow at
6 months.
Change in olfaction
UPSIT Pinto Median (IQR), 3 (2 to 14) vs.
−4 (−5 to −2); p < 0.31
Not estimable 1 (14) Low (+) median value means increased smell

















3—nasal obstruction, 2—shortness of
breath, 1—allergy, 8—common cold,
1—gastroenteritis, 1—shoulder pain,
2—otitis media, 1—left ulnar
hypoesthesia, 1—general myalgia) vs.
placebo (1—asthma exacerbation,
1—frontal headache, 3—nasal
obstruction, 1—shortness of breath,
1—jaundice, 1—acute sinusitis); no
adverse events occurred in Pinto et al.
trial
See comment 1 (23);
1 (14)
Low Common cold was the only adverse event to
occur more frequently with treatment (p = 0.02).
Change in systemic IgE levels
Not reported in any studies N/A N/A
Change in spirometric results
Not reported in any studies N/A N/A
CI confidence interval, IQR interquartile range, SF-36 36-Item Short Form Health Survey, AQLQ Asthma Quality of Life Questionnaire, RSOM-31 Rhinosinusitis Outcome Measure 31, TNSS Total Nasal Symptom Severity,
SNOT-20 Sinonasal Outcome Test 20, PNIF peak nasal inspiratory flow, UPSIT University of Pennsylvania Smell Identification Test, N/A not available













important limitations of the included studies. Finally, each
of the included studies had a moderate risk of bias, which
can lead to an overestimation of the treatment effects and
decreases the confidence as to whether the observed
effects are the “true” effects of treatment. Future research
evaluating the effectiveness and safety of anti-IgE mono-
clonal antibody therapy should take the aforementioned
limitations into consideration. The improved study design
will serve as an opportunity to abridge current evidence
gaps by identifying the true benefits and adverse events
associated with the therapy with an optimal threshold.
Future trials should include the core outcomes of a
patient CRS symptom score (e.g., SNOT-22), health-
related quality of life, olfactory testing, and a clinical
polyp score for CRS with polyp patients.
A limitation of this systematic review is that we could
have potentially missed otherwise eligible studies in other
languages as our inclusion criteria were limited to studies
reported in the English language. However, based on the
small number of included studies, we feel that the likeli-
hood of studies existing in other languages is quite low. In
addition, our review only had one reviewer involved in the
screening and eligibility assessment of relevant articles.
Finally, we did not address anti-IgE monoclonal antibody
as an adjuvant therapy. In the future, it may be beneficial
to assess whether there is greater effectiveness in using
Table 5 GRADE assessments for the body of evidence for each outcome and judgment of the overall quality of evidence





Change in CT score
Lund-McKay Score 16 weeks Moderate limitation Not relevant No serious
indirectness
Serious imprecision Unlikely Low
Percent opacification on CT 6 months Moderate limitation Not relevant No serious
indirectness
Serious imprecision Unlikely Low






Moderate limitation Not relevant No serious
indirectness
Serious imprecision Unlikely Low
Change in quality of life
SF-36 16 weeks Moderate limitation Not relevant No serious
indirectness
Serious imprecision Unlikely Low
AQLQ 16 weeks Moderate limitation Not relevant No serious
indirectness
Serious imprecision Unlikely Low
RSOM-31 16 weeks Moderate limitation Not relevant No serious
indirectness
Serious imprecision Unlikely Low
TNSS 6 months Moderate limitation Not relevant No serious
indirectness
Serious imprecision Unlikely Low
SNOT-20 6 months Moderate limitation Not relevant No serious
indirectness






6 months Moderate limitation Not relevant No serious
indirectness
Serious imprecision Unlikely Low
Change in nasal airflow
PNIF 6 months Moderate limitation Not relevant No serious
indirectness
Serious imprecision Unlikely Low
Change in olfaction
UPSIT 6 months Moderate limitation Not relevant No serious
indirectness
Serious imprecision Unlikely Low
Adverse events 16 weeks;
6 months
Moderate limitation Not relevant No serious
indirectness
Serious imprecision Unlikely Low
SF-36 36-Item Short Form Health Survey, AQLQ Asthma Quality of Life Questionnaire, RSOM-31 Rhinosinusitis Outcome Measure 31, TNSS Total Nasal Symptom
Severity, SNOT-20 Sinonasal Outcome Test 20, PNIF peak nasal inspiratory flow, UPSIT University of Pennsylvania Smell Identification Test
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anti-IgE monoclonal antibody alongside the prevailing
therapeutic interventions.
Conclusions
There is currently insufficient evidence to determine
whether anti-IgE monoclonal antibody therapy is more
effective or safer than placebo for the treatment of CRS. A
sufficiently powered, high-quality trial is needed to further
assess its effectiveness in this population. Determining its
effectiveness and safety may have important implications
for the management paradigm of some patients with CRS
who do not respond to conventional treatment regimens.
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1. exp Antibodies, Monoclonal/tu [Therapeutic Use]
2. exp Antibodies, Anti-Idiotypic/tu [Therapeutic Use]
3. exp Antibodies, Monoclonal, Humanized/tu
[Therapeutic Use]
4. anti IgE.mp.
5. (anti adj1 IgE).mp. [mp = title, abstract, original
title, name of substance word, subject heading word,
keyword heading word, protocol supplementary
concept word, rare disease supplementary concept
word, unique identifier]
6. anti IgE therapy.mp.
7. omalizumab.mp.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp Sinusitis/
10. sinusitides.tw.
11. 9 or 10
12. exp Rhinitis/
13. (catarrh* adj2 nasal).tw.
14. (rhinitis adj2 nonseasonal).tw.
15. 12 or 13 or 14
16. 11 and 15
17. exp Nasal Polyps/
18. polyp* nasal.tw.
19. nasal polyp*.tw.
20. 17 or 18 or 19
21. 16 or 20
22. 8 and 21
Abbreviations
AQLQ: Asthma Quality of Life Questionnaire; CI: confidence interval;
CRS: chronic rhinosinusitis; CT: computed tomography;
CONSORT: Consolidated Standards of Reporting Trials; ICTRP: International
Clinical Trials Registry Platform; MD: mean difference; PRISMA: Preferred
Reporting Items for Systematic Reviews and Meta-analyses; PNIF: peak nasal
inspiratory flow; RCT: randomized controlled trial; RSOM-31: Rhinosinusitis
Outcome Measure 31; SF-36: 36-Item Short Form Health Survey;
SNOT-20: Sinonasal Outcome Test 20; TNSS: Total Nasal Symptom
Severity; UPSIT: University of Pennsylvania Smell Identification Test.
Competing interests
We declare that we have no conflicts of interest.
Authors’ contributions
SK had the idea for the project. CH, AT, and SK designed the study. SK
undertook searches of the published work. JQ and JB independently
performed data extraction and quality assessment by reading articles in
full-text. Statistical analyses and interpretation of the data were done by AS.
CH and AT designed the tables and figures. CH wrote the manuscript, and
AT, JQ, JB, AS, and SK revised it critically for important intellectual content.
All authors had full access to the study data and approved the final version.
Author details
1Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. 2Department
of Pathology and Laboratory Medicine, Dalhousie University, Halifax, NS,
Canada. 3Department of Otolaryngology-Head and Neck Surgery, University
of Ottawa, The Ottawa Hospital, 737 Parkdale Ave., Room 459, Ottawa,
Ontario K1Y 1J8, Canada. 4Center for Practice Changing Research, Ottawa
Hospital Research Institute (OHRI), Ottawa, ON, Canada. 5Department of
Clinical Epidemiology, University of Ottawa, Ottawa, ON, Canada.
Received: 4 February 2015 Accepted: 9 November 2015
References
1. Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in
Canadians. Laryngoscope. 2003;113:1199–205.
2. Lethbridge-Cejku M, Schiller JS, Bernadel L. Summary health statistics for
U.S. adults: national health interview survey, 2002. Vital Health Stat 10
2004;1-151
3. Lethbridge-Cejku M, Rose D, Vickerie J. Summary health statistics for
U.S. adults: national health interview survey, 2004. Vital Health Stat 10
2006;1-164
4. Benninger MS, Ferguson BJ, Hadley JA, Hamilos DL, Jacobs M, Kennedy DW,
et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and
pathophysiology. Otolaryngol Head Neck Surg. 2003;129:S1–32.
5. Gliklich RE, Metson R. The health impact of chronic sinusitis in patients
seeking otolaryngologic care. Otolaryngol Head Neck Surg. 1995;113:104–9.
6. Macdonald KI, McNally JD, Massoud E. The health and resource utilization of
Canadians with chronic rhinosinusitis. Laryngoscope. 2009;119:184–9.
7. Kilty SJ, McDonald JT, Johnson S, Al-Mutairi D. Socioeconomic status: a
disease modifier of chronic rhinosinusitis? Rhinology. 2011;49:533–7.
8. Soler ZM, Wittenberg E, Schlosser RJ, Mace JC, Smith TL. Health state utility
values in patients undergoing endoscopic sinus surgery. Laryngoscope.
2011;121:2672–8.
9. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al.
European position paper on rhinosinusitis and nasal polyps 2012. Rhinol
Suppl. 2012;23:1–298.
10. Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in initial
immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis
with nasal polyps. Am J Rhinol Allergy. 2014;28:192–8.
11. Seshadri S, Rosati M, Lin DC, Carter RG, Norton JE, Choi AW, et al. Regional
differences in the expression of innate host defense molecules in sinonasal
mucosa. J Allergy Clin Immunol. 2013;132:1227–30. e5.
12. Vlaminck S, Vauterin T, Hellings PW, Jorissen M, Acke F, Van Cauwenberge P,
et al. The importance of local eosinophilia in the surgical outcome of
chronic rhinosinusitis: a 3-year prospective observational study. Am J Rhinol
Allergy. 2014;28:260–4.
13. Grundmann SA, Hemfort PB, Luger TA, Brehler R. Anti-IgE (omalizumab):
a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin
Immunol. 2008;121:257–8.
14. Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K, et al. Efficacy
of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma.
Ann Allergy Asthma Immunol. 2013;110:387–8.
15. Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal
polyposis: a pilot study. Am J Rhinol. 2007;21:428–32.
Hong et al. Systematic Reviews  (2015) 4:166 Page 10 of 11
16. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al.
Omalizumab is effective in allergic and nonallergic patients with nasal
polyps and asthma. J Allergy Clin Immunol. 2013;131:110–6.
17. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A
randomized, double-blind, placebo-controlled trial of anti-IgE for chronic
rhinosinusitis. Rhinology. 2010;48:318–24.
18. Vennera Mdel C, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen M. Efficacy of
omalizumab in the treatment of nasal polyps. Thorax. 2011;66:824–5.
19. Guglielmo M, Gulotta C, Mancini F, Sacchi M, Tarantini F. Recalcitrant nasal
polyposis: achievement of total remission following treatment with
omalizumab. J Investig Allergol Clin Immunol. 2009;19:158–9.
20. Gonzalez-Diaz SN, Rangel-Garza LR. Omalizumab efficiency in patients with
allergic rhinitis and chronic sinusitis. World Allergy Organ J. 2014;7 Suppl 1:9.
21. National Institute for Health Research. PROSPERO—International Prospective
Register of Systematic Reviews (2013). Available online at: http://www.crd.
york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014007600. Accessed
November 22, 2014.
22. Moher D, Liberati A, Tetzlaff J, Altman DG, Group PRISMA. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. Ann Intern Med. 2009;151:264–9.
23. Higgins JP, Altman DG, Gotzsche PC, Jüni P, Moher D, Oxman AD, et al. The
Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.
BMJ. 2011;343:d5928.
24. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P,
et al. GRADE: an emerging consensus on rating quality of evidence and
strength of recommendations. BMJ. 2008;336:924–6.
25. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE
guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J
Clin Epidemiol. 2011;64:407–15.
26. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE
guidelines: 5. Rating the quality of evidence—publication bias. J Clin
Epidemiol. 2011;64:1277–82.
27. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al.
GRADE guidelines: 6. Rating the quality of evidence—imprecision. J Clin
Epidemiol. 2011;64:1283–93.
28. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al.
GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin
Epidemiol. 2011;64:1294–302.
29. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al.
GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin
Epidemiol. 2011;64:1303–10.
30. Hopkins C, Browne JP, Slack R, Lund V, Brown P. The Lund-Mackay staging
system for chronic rhinosinusitis: how is it used and what does it predict?
Otolaryngol Head Neck Surg. 2007;137:555–61.
31. Hopkins C, Slack R, Lund V, Brown P, Copley L, Browne J. Long-term
outcomes from the English national comparative audit of surgery for nasal
polyposis and chronic rhinosinusitis. Laryngoscope. 2009;119:2459–65.
32. Gevaert P, Nouri-Aria KT, Wu H, Harper CE, Takhar P, Fear DJ, et al.
Local receptor revision and class switching to IgE in chronic
rhinosinusitis with nasal polyps. Allergy. 2013;68:55–63.
33. Porter PC, Lim DJ, Maskatia ZK, Mak G, Tsai CL, Citardi MJ, et al. Airway
surface mycosis in chronic
TH2-associated airway disease. J Allergy Clin Immunol. 2014;134:325–31.
34. Rosenfeld RM, Andes D, Bhattacharyya N, Cheung D, Eisenberg S, Ganiats
TG, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck
Surg. 2007;137:S1–31.
35. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma
in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.
36. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M,
et al. Efficacy and tolerability of anti-immunoglobulin E therapy with
omalizumab in patients with concomitant allergic asthma and
persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709–17.
37. Verbruggen K, Van Cauwenberge P, Bachert C. Anti-IgE for the treatment of
allergic rhinitis—and eventually nasal polyps? Int Arch Allergy Immunol.
2009;148:87–98.
38. Schulz KF, Altman DG, Moher D, Group CONSORT. CONSORT 2010
statement: updated guidelines for reporting parallel group randomized
trials. Ann Intern Med. 2010;152:726–32.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hong et al. Systematic Reviews  (2015) 4:166 Page 11 of 11
